In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
The Burden of Choice
Dr. Martin Lachs, Dr. Reinhard Eisebitt and Dr. Valerii Fedorov contribute to this article in Clinical Oncologist Daily on ICON's decision to invest in a Cancer Moonshot project using quantum computing.
-
ICON Oncology’s Opinion of How We Can Reach for the Stars With a Moonshot
Dr. Martin Lachs, Dr. Reinhard Eisebitt and Dr. Valerii Fedorov contribute to this article in Clinical Oncologist Daily on ICON's decision to invest in a Cancer Moonshot project using quantum computing.
-
APAC is the fastest growing market for CRO industry
In this article, Mary Pan outlines the growth and trends of clinical trials in the APAC region.
-
Effective Sponsor-CRO Collaboration
In this PharmaVOICE article, read commentary from Dr. Phil Birch on effectivesponsor-CRO collaboration.
-
ICON Recognised for Excellence in Vaccine Development
Coverage of ICON's recent award at the ViE Awards. these awards honor individuals and organisations that continually set standards of excellence and have made outstanding achievements in the vaccine industry.
-
Predatory Journals Are Back in the Firing Line
Learn how to spot apredatory journalwith these tips from PubsHub.
-
Overcoming Four Challenges to Successful Rare Disease Drug Development
ICON contributed to this article in Pharmafocus relating to overcoming four challenges to greatly improve the chances for a successful rare or “orphan” drug trial.
-
Why a Patient's Experience with a Drug Matters
Patient reported outcomesare often the primary endpoints in FDA approved pain drugs. Andy Smith shares his insights inMednous.
-
PRO Instruments to Improve Endpoints for Antibacterial Drug Trials
Brittany Erana contributes to this article that features theFDA's selection ofICON to validate PRO instruments used to access clinical endpoints in antibacterial drug trials.
-
Cell and Gene Therapies: On Course for Commercial Success?
Rebecca Walker contributes to this PMLiVE article oncell and gene therapies.
